Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

ganitumab 2Paclitaxel 2conatumumab 1Carboplatin 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Insulin-Like Growth Factor I, Resistance To × Clear all
NCT00889382 2024-11-20

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Astellas Pharma Inc

Phase 1/2 Completed
152 enrolled
Gynecologic

Insulin-Like Growth Factor I, Resistance To, Ovarian Neoplasms

NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NantCell, Inc.

Phase 1/2 Completed
138 enrolled 19 charts
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡